PIK3CB and neoplasm: Furthermore, in the case of acquired resistance, palbociclib is unable to inhibit the Rb signal, and thus loses control of tumor cell growth, while targeted PI3K therapy can block PI3K/AKT/mTOR pathway, thus effectively inhibiting the proliferation of resistant cells [12].